Date: 2017-07-07
Type of information: Capital increase
Company: Biophytis (France)
Investors: Bracknor Investment Group (Dubai)
Amount: € 18,7 million
Funding type: capital increase - private placement
Planned used: These funds will be used to support the phase 2b SARA-OBS/SARA-INT clinical study aimed at testing Sarconeos, for the treatment of sarcopenia.
Others:
- • On July 7, 2017, Biophytis announces the issuance of
300 Bonds Redeemable in Cash or New or Existing Shares (ORNANE), for a total amount of €3 million, simultaneously with the issuance of 205,959 share subscription warrants.
The 300 ORNANE issued will have a 12-month maturity from issuance. The holder may request at any time their redemption during their maturity period, and on this occasion the Company will be able to redeem the ORNANE in cash. The ORNANE will not be subject to a request for admission to trading on the Euronext Growth market.
- • On May 16, 2017, Biophytis announced the issuance of of
300 Bonds Redeemable in Cash or New or Existing Shares (ORNANE), for a total amount €3 million, simultaneously with the issuance of 225,225 share subscription warrants.
- • On April 4, 2017, Biophytis announced that it has
- gathered funding to conduct its phase 2b SARA-OBS/SARA-INT clinical study aimed at testing Sarconeos, for the treatment of sarcopenia. First, a capital increase subscribed by
several private investors among which Bracknor Fund, and the management, of an amount of €3.7 million was completed by issuing 1,310,431 new shares at a price of €2.85 per share. Secondly, a line of funding that could reach €15 million was set up with Bracknor Fund in the form of 1,500 note
warrants for Bonds Redeemable in Cash or New or Existing Shares (ORNANE), at a par value of €10,000 each, combined with Share Subscription Warrants (BSAs), together referred to as ORNANEBSA. Note warrantswere fully subscribed by Bracknor Fund. Bracknor Fund undertakes to exercise the warrants for 36 months, at Biophytis’ request, through
successive tranches of €3 million each (€15 million in total).
Therapeutic area: Ageing diseases - Muscle disorders - Ophtalmological diseases
Is general: Yes
